Corient Private Wealth
RCKT icon

Corient Private Wealth’s Rocket Pharmaceuticals RCKT Stock Holding History

Corient Private Wealth’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$112K Sell
32,318
-23,730
-42% -$94.3K ﹤0.01% 2665
2025
Q4 		$197K Buy
+56,048
New +$192K ﹤0.01% 2597
2025
Q3 		– Sell
-22,897
Closed -$56.1K – 2657
2025
Q2 		$56.1K Buy
+22,897
New +$116K ﹤0.01% 2376

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Corient Private Wealth's RCKT Position: Q1 2026 in Review

Corient Private Wealth reduced its Rocket Pharmaceuticals (RCKT) stake by 42% in Q1 2026, selling an estimated $94.3K and leaving 32,318 shares worth $112K. The position accounts for ﹤0.01% of the portfolio, ranked #2665.

Corient Private Wealth first reported a position in RCKT in Q2 2025 and has held it in 3 quarters since. The position peaked at $197K in Q4 2025. 198 funds tracked by Wall St. Rank hold RCKT as of Q1 2026.

  • Corient Private Wealth held 32,318 shares of Rocket Pharmaceuticals worth $112K as of Q1 2026.
  • Corient Private Wealth sold 23,730 Rocket Pharmaceuticals shares in Q1 2026, an estimated $94.3K.
  • Rocket Pharmaceuticals made up ﹤0.01% of Corient Private Wealth's portfolio in Q1 2026, its #2665 holding.
  • Corient Private Wealth first reported a position in Rocket Pharmaceuticals in Q2 2025 and has held it in 3 quarters since.
  • Corient Private Wealth's Rocket Pharmaceuticals position peaked at $197K in Q4 2025.
  • 198 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2026.

Based on Corient Private Wealth's 13F filing for Q1 2026, filed 15 May 2026.